| Literature DB >> 27185741 |
Susanna K P Lau1,2,3,4, Wang-Ngai Chow1, Chuen-Hing Foo1, Shirly O T Curreem1, George Chi-Shing Lo1, Jade L L Teng1, Jonathan H K Chen1, Ricky H Y Ng5, Alan K L Wu6, Ingrid Y Y Cheung7, Sandy K Y Chau5, David C Lung8, Rodney A Lee6, Cindy W S Tse7, Kitty S C Fung5, Tak-Lun Que8, Patrick C Y Woo1,2,3,4.
Abstract
Unlike Elizabethkingia meningoseptica, the clinical importance of E. anophelis is poorly understood. We determined the clinical and molecular epidemiology of bacteremia caused by Elizabethkingia-like species from five regional hospitals in Hong Kong. Among 45 episodes of Elizabethkingia-like bacteremia, 21 were caused by Elizabethkingia, including 17 E. anophelis, three E. meningoseptica and one E. miricola; while 24 were caused by other diverse genera/species, as determined by 16S rRNA gene sequencing. Of the 17 cases of E. anophelis bacteremia, 15 (88%) were clinically significant. The most common diagnosis was pneumonia (n = 5), followed by catheter-related bacteremia (n = 4), neonatal meningitis (n = 3), nosocomial bacteremia (n = 2) and neutropenic fever (n = 1). E. anophelis bacteremia was commonly associated with complications and carried 23.5% mortality. In contrast, of the 24 episodes of bacteremia due to non-Elizabethkingia species, 16 (67%) were clinically insignificant. Compared to non-Elizabethkingia bacteremia, Elizabethkingia bacteremia was associated with more clinically significant infections (P < 0.01) and positive cultures from other sites (P < 0.01), less polymicrobial bacteremia (P < 0.01), and higher complication (P < 0.05) and mortality (P < 0.05) rates. Elizabethkingia bacteremia is predominantly caused by E. anophelis instead of E. meningoseptica. Elizabethkingia bacteremia, especially due to E. anophelis, carries significant morbidity and mortality, and should be considered clinically significant unless proven otherwise.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27185741 PMCID: PMC4868968 DOI: 10.1038/srep26045
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Phylogenetic tree showing the relationship of the 45 Elizabethkingia-like blood culture isolates to related bacterial species using 16S rRNA gene sequence analysis.
The tree was constructed by maximum likelihood method using General Time Reversible model and Escherichia coli (CP010304) as the root. A total of 1325 nucleotide positions were included in the analysis. Bootstrap values were calculated from 1000 replicates. The scale bar indicates the number of substitutions per site. Names and accession numbers are given as cited in GenBank database.
Characteristics of the 45 patients with bacteremia caused Elizabethkingia-like organisms
| Characteristics | Number of patients (%) | ||
|---|---|---|---|
| Non- | |||
| Sex (male:female) | 11:10 | 13:11 | 0.90 |
| Underlying diseases | 19 (90.5) | 24 (100) | 0.12 |
| Hospital- vs community-acquireda | 15:4 | 7:1 | 0.60 |
| Diagnosisb | |||
| Biliary tract infection | 2 (9.5) | 0 (0) | 0.12 |
| Catheter-related bacteremia | 5 (23.8) | 1 (4.2) | 0.05 |
| Community-acquired pneumonia | 3 (14.3) | 0 (0) | 0.06 |
| Neonatal meningitis | 3 (14.3) | 0 (0) | 0.06 |
| Neutropenic fever | 1 (4.8) | 2 (8.3) | 0.63 |
| Nosocomial bacteremia | 3 (14.3) | 5 (20.8) | 0.57 |
| Nosocomial pneumonia | 2 (9.5) | 0 (0) | 0.12 |
| Primary bacteremia | 0 (0) | 1 (4.2) | 0.34 |
| Pseudobacteremia | 2 (9.5) | 16 (76.1) | 0.00009 |
| >1 positive blood cultures | 3 (14.3) | 1 (4.2) | 0.23 |
| Polymicrobial bacteremia | 0 (0) | 10 (41.7) | 0.0008 |
| Positive cultures from other sites | 8 (38.1) | 1 (4.2) | 0.005 |
| Complications | 7 (33.3) | 1 (4.2) | 0.01 |
| Attributable mortality | 4 (19.0) | 0 (0) | 0.025 |
aexcluding pseudobacteremia.
bThe percentages add up to more than 100% because some patients have more than one diagnosis.
cby Chi-square test.
Clinical characteristics of patients with Elizabethkingia bacteremia.
| Case/strain no. | Sex | Age | Underlying diseases | Diagnosis | Community- or hospital-acquired | No. of positive blood cultures (concomitant isolates) | Other culture-positive specimens | Antibiotic treatment | Complications/outcomee |
|---|---|---|---|---|---|---|---|---|---|
| EA1 | M | 54 | DM, hyperlipidemia, ischemic cardiomyopathy | Nosocomial pneumonia | HA | 1 | None | Piperacillin-tazobactam | Acute pulmonary edema, CHF, survived |
| EA2 | M | 65 | HT, DM, CAD, PVD, RAS, hyperlipidemia, carotid stenosis | Pseudobacteremia | NA | 1 | None | Cloxaciillin and levofloxacin, then amoxicillin-clavulanate | Survived |
| EA3 | F | 1m | Prematurity, twin, RDS, PDA | Catheter-related bacteremia | HA | 3 | None | Vancomycin, cefoperazone-sulbactam | Multi-organ failure, died |
| EA4 | F | 8d | Imperforated anus, rectovaginal fistula | Neonatal meningitis | HA | 2 | CSF | Vancomycin and rifampicin | Survived |
| EA5 | M | 65 | COPD, CAD, CHF, AF, CRHD, right hip AVN | Community-acquired pneumonia | CA | 1 | Sputum | Ciprofloxacin | Survived |
| EA6 | M | 37 | Dilated cardiomyopathy, CAD | Nosocomial bacteremia | HA | 1 | None | Ciprofloxacin | DIC, survived |
| EA7 | F | 64 | HT, hyperlipidemia, stage 4 DLBC lymphoma | Neutropenic fever, severe mucositis | HA | 2 | None | Meropenem | Septic shock, haematemesis, died |
| EA8 | M | 68 | HT, CRF, AAA | Nosocomial bacteremia | HA | 1 | Tracheal aspirate | Levofloxacin and vancomycin | Acute renal failure, died |
| EA9 | M | 73 | CA hypopharynx, CA ampulla of Vater | Pseudobacteremia | NA | 1 | None | Cefuroxime | Survived |
| EA10 | M | 51 | None | Community-acquired pneumonia | CA | 1 | Sputum | Ampicillin-sulbactam, then ciprofloxacin | Survived |
| EA11 | F | 104 | HT, CAD, CVA, nephrotic syndrome | Community-acquired pneumonia | CA | 1 | None | Amoxicillin-clavulanate | Died |
| EA12 | M | 59 | obesity, DM, CAD | Catheter-related bacteremia, drip site cellulitis | HA | 1 | None | Levofloxacin | Survived |
| EA13 | F | 35 | Epilepsy, HT, ESRF on HD | Catheter-related bacteremia | HA | 1 | None | Levofloxacin | Survived |
| EA14 | M | 58 | CRHD with AVR, ESRF on HD | Catheter-related bacteremia | HA | 1 | Catheter tip | Piperacillin-tazobactam, then levofloxacin | Septic shock, survived |
| EA15 | M | 88 | COPD, old PTB | Nosocomial (aspiration) pneumonia | HA | 1 | None | Levofloxacin | Survived |
| HKU36 | M | 21d | None | Neonatal meningitis | HA | 1 | CSF | Vancomycin, piperacillin and rifampicin | Survived |
| HKU38 | F | 1d | Apnea of prematurity | Neonatal meningitis | HA | 1 | CSF | Vancomycin, piperacillin-tazobactam and rifampicin | metabolic acidosis, IVH, survived |
| EME1 | M | 51 | Asthma, HT, scoliosis, MSSA infective spondylitis | Nosocomial bacteremia | HA | 1 | None | Ticarcillin-clavulanate | Survived |
| EME2 | M | 52 | Biliary pancreatitis, RPC, cholecystectomy, cirrhosis with biliary stent | Post-cholangiogram acute cholangitis | HA | 1 | None | Levofloxacin and metronidazole | Survived |
| EME3 | F | 89 | HT, AF, painless obstructive jaundice on palliative stenting | Biliary sepsis | CA | 1 | None | Levofloxacin | Survived |
| EMI1 | M | 54 | DM, hyperlipidemia, ischemic cardiomyopathy | Catheter-related bacteremia | HA | 1 | CVP catheter | Levofloxacin | Survived |
aAAA, abdominal aortic aneurysm; AF, atrial fibrillation; AVN, avascular necrosis; AVR, atrial valve replacement; CA, carcinoma; CA, community-acquired; CAD, coronary artery disease; CHF, congestive heart failure; COPD; chronic obstructive pulmonary disease; CRF, chronic renal failure; CRHD, chronic rheumatic heart disease; CSF, cerebrospinal fluid; CVA, cerebrovascular accident; CVP, central venous pressure; DIC, disseminated intravascular coagulation; DLBC, diffuse large B cell; DM, diabetes mellitus; ESRF, end-stage renal failure; HA, hospital-acquired; HD, hemodialysis; HT, hypertension; IVH, intraventricular hemorrhage; MSSA, methicillin-sensitive Staphylococcus aureus; NA, not applicable; PDA, patent ductus arteriosus; PTB, pulmonary tuberculosis; PVD, peripheral vascular disease; RAS, renal artery stenosis; RDS, respiratory distress syndrome; RPC, recurrent pyogenic cholangitis.
Clinical characteristics of patients with non-Elizabethkingia bacteremia.
| Case/ strain no. | Sex | Age | Underlying diseases | Diagnosis | Community- or hospital-acquired | No. of positive blood cultures (concomitant isolates) | Other culture-positive specimens | Treatment + removal of catheter | Complications + outcome |
|---|---|---|---|---|---|---|---|---|---|
| Potentially novel | |||||||||
| C13 | M | 64 | Metastatic pancreatic carcinoma, sepsis | Postmortem pseudobacteremia | NA | 1 | None | NA | Died (non-attributable) |
| C15 | M | 68 | Head injury | Pseudobacteremia | NA | 1 ( | No | Amoxicillin-clavulanate | Survived |
| C1 | M | 82 | HT, gout, BPH, bilateral hydronephrosis and hydroureter | Nosocomial bacteremia | HA | 1 | None | Piperacillin-tazobactam, then levofloxacin | Survived |
| C2 | F | 48 | Stage IV DLBC lymphoma | Catheter-related bacteremia, neutropenic fever | HA | 6 ( | Central catheter | Imipenem-cilastatin and amikacin | Septic shock, survived |
| C9 | M | 56 | COPD, pneumothorax | Nosocomial bacteremia | HA | 1 | None | Ticarcillin-clavulanate, levofloxacin | Survived |
| C14 | M | 1 | Cow milk allergy | Nosocomial bacteremia | HA | 1 | None | Piperacillin-tazobactam | Survived |
| C8 | F | 76 | DM, HT, CVA, CHF, AAA, PVD, hyperlipidemia | Pseudobacteremia | NA | 1 | None | None | Survived |
| C12 | F | 51 | AML | Neutropenic fever | HA | 1 ( | None | Piperacillin-tazobactam, vancomycin | Survived |
| C3 | F | 58 | Hyperlipidemia, IgA nephropathy, Multiple myeloma | Pseudobacteremia | NA | 1 ( | None | Levofloxacin, piperacillin-tazobactam | Survived |
| C4 | F | 49 | DM, CRF, bilateral hydronephrosis, perinephric and psoas abscess | Pseudobacteremia | NA | 1 ( | None | Cefuroxime, ampicillin, levofloxacin | Survived |
| C5 | M | 78 | HT, gout, CA caecum with metastases, thyroidectomy | Pseudobacteremia | NA | 1 ( | None | Amoxicillin-clavulanate, ciprofloxacin | Survived |
| C6 | F | 57 | CA rectum, mania, small bowel obstruction | Pseudobacteremia | NA | 1 ( | None | Amoxicillin-clavulanate | Survived |
| C7 | M | 84 | HT, AF,CRHD, CVA, gout, BPH COPD | Pseudobacteremia | NA | 1 | None | Amoxicillin-clavulanate | Survived |
| C10 | F | 56 | Acute encephalopathy, aspiration pneumonia, sepsis | Postmortem pseudobacteremia | NA | 1 ( | None | NA | Died (non-attributible) |
| C11 | M | 85 | DM, DU, BPH | Pseudobacteremia | NA | 1 | None | Amoxicillin-clavulanate | Survived |
| F1 | F | 30 | SLE, lupus nephritis | Nosocomial (post-transfusion) bacteremia | HA | 1( | None | Levofloxacin | Survived |
| P1 | M | 90 | CAD, COPD, DM, BPH | Primary bacteremia | CA | 1 | None | Ceftriaxone | Survived |
| P2 | M | 1d | RDS, congenital pneumonia | Pseudobacteremia | NA | 1 | None | Penicillin and netilmicin | Survived |
| P3 | F | 99 | COPD, CVA, intertrochanteric fracture | Pseudobacteremia | NA | 1 | None | Amoxicillin-clavulanate | Survived |
| P4 | M | 56 | COPD, BPH, PTB | Pseudobacteremia | NA | 1 | None | Levofloxacin | Survived |
| P5 | M | 52 | NPC, thyroidectomy, hypothyroidism | Nosocomial (post-transfusion) bacteremia | HA | 1 | None | Piperacillin-tazobactam | Survived |
| P6 | F | 1m | Sepsis, hypoglycemia | Pseudobacteremia | NA | 1 | None | Cefotaxime | Survived |
| S1 | M | 94 | COPD, cor pulmonale, BPH, gout, Shy-Drager syndrome, CAD | Pseudobacteremia | NA | 1 ( | None | Cotrimoxazole | Survived |
| Potentially novel | |||||||||
| W1 | F | 18d | RSV pneumonia | Pseudobacteremia | NA | 1 | None | Ampicillin, netilmicin and erythromycin | Survived |
aAAA, abdominal aortic aneurysm; AF, atrial fibrillation; AML, acute myeloid leukemia; BPH, benign prostatic hyperplasia; CA, carcinoma; CA, community-acquired; CAD, coronary artery disease; CHF, congestive heart failure; CNS, coagulase-negative Staphylococcus; COPD; chronic obstructive pulmonary disease; CRF, chronic renal failure; CRHD, chronic rheumatic heart disease; CVA, cerebrovascular accident; DLBC, diffuse large B cell; DM, diabetes mellitus; DU, Duodenal ulcer; HA, hospital-acquired; HT, hypertension; MSSA, methicillin-sensitive Staphylococcus aureus; NA, not applicable; NPC, nasopharyngeal carcinoma; PTB, pulmonary tuberculosis; PVD, peripheral vascular disease; RDS, respiratory distress syndrome; RSV, respiratory syncytial virus; SLE, systemic lupus erythematosus.
Figure 2Results of MALDI-TOF MS identification of the 21 Elizabethkingia strains.
In panel (A), representative MALDI-TOF MS spectra of the three Elizabethkingia species are shown. In panel (B), dendrogram was generated from hierarchical clustering of MALDI-TOF MS spectra of 21 Elizabethkingia isolates and reference strains of E. meningoseptica and E. miricola, using ClinProTools 3.0 (Bruker Daltonics, Germany). Distances are displayed in relative units.
Figure 3Pulsed-field gel electrophoresis (PFGE) analysis of the 17 E. anophelis isolates and E. anophelis type strain R26T.
(lane 1 = EA1, lane 2 = EA2, lane 3 = EA3, lane 4 = EA4, lane 5 = EA5, lane 6 = EA6, lane 7 = EA7, lane 8 = EA8, lane 9 = EA9, lane 10 = EA10, lane 11 = EA11, lane 12 = EA12, lane 13 = EA13, lane 14 = EA14, lane 15 = EA15, lane 16 = HKU38, lane 17 = HKU36, lane 18 = R26T, M = lambda marker). In Panel (A), PFGE was performed using CHEF Mapper XA system (Bio-Rad) and restriction endonuclease XbaI. Results showed that the 17 isolates possessed distinct PFGE patterns. In Panel (B), dendrogram was constructed with PFGE data by similarity and clustering analysis using the Dice coefficient (1% tolerance and 0.5% optimization) and unweighted pair-group method using average linkages with GelCompar II.